Phase 3 N=28 Randomized Double-blind Treatment

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

Migraine

Bottom Line

View on ClinicalTrials.gov: NCT02665273 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2020

Primary outcome: Primary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Greater occipital nerve block (Procedure); Bupivacaine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Montefiore Medical Center
Primary completion: Jan 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Achieve Freedom From Headache	4; 0	—
SECONDARY Sustained Headache Relief	3; 0	—
SECONDARY Would Want the Same Treatment Again During a Subsequent Migraine	5; 3	—

Summary

This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.

Eligibility Criteria

Inclusion Criteria

ED patient with acute migraine or probable migraine
Fail first line therapy with metoclopramide

Exclusion Criteria

Can't obtain consent
Concern for secondary headache
Skull defect
Propensity for bleeding
Overlying infection
Pregnancy
Allergy, intolerance study medication

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02665273). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.